Research Topics
| Lawrence C PaolettiSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cellsHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Hum Vaccin 4:370-4. 2008..These results represent the first important step in developing a standardized, high-throughput OPA that could be used to assess the functional activity of vaccine-induced antibody and potentially serve as a surrogate of efficacy...- Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbitsLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Hum Vaccin 4:435-43. 2008..e., it was non-teratogenic). In addition, that III-TT lot 3-1-96 was found to be safe and immunogenic in two clinical studies involving healthy non-pregnant adults supports a clinical evaluation of this vaccine in pregnant women... - Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccinesHsiao Hui Yang
Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
Infect Immun 75:3455-61. 2007..These results suggest that the rBCP(DeltaIgA) could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP... - Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinHsiao Hui Yang
Department of Medicine, Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Vaccine Immunol 15:1035-41. 2008..Thus, the potential exists for the inclusion of rAlp3 in a GBS vaccine formulated to provide multiserotype coverage... - Molecular characterization of nontypeable group B streptococcusSrinivas V Ramaswamy
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA
J Clin Microbiol 44:2398-403. 2006..These data shed new light on the antigenic complexity of NT GBS isolates, information that can be valuable in the formulation of an effective GBS vaccine... 
Identification of novel cps locus polymorphisms in nontypable group B StreptococcusSrinivas V Ramaswamy
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
J Med Microbiol 55:775-83. 2006..Collectively, genetic and immunologic analyses revealed that these NT isolates expressing R1, R4 proteins have a genetic profile consistent with that of type V, an emergent, antigenically diverse and increasingly prevalent GBS serotype...- A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B StreptococcusHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Hum Vaccin 5:461-6. 2009..Quantitative functional antibody determinations using the flOPA may serve as a surrogate measure of GBS vaccine effectiveness in lieu of traditional phase 3 efficacy trials... - Conjugate vaccines against group B Streptococcus types IV and VIILawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Infect Dis 186:123-6. 2002..If needed, types IV and VII CPS conjugate vaccines of the design described can be added to the formulation of a multivalent GBS vaccine... - Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switchingHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Institute for Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:5903-8. 2008..Targeted chemical engineering of a carbohydrate to create a molecule less like host self may be a rational approach for improving other glycoconjugates... - Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14Hilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 70:1724-38. 2002..When present, these vaccine-induced cross-reacting antibodies conferred in vitro antibody-mediated opsonophagocytosis and killing of both GBS III and Pn14, two pathogens that cause invasive disease in young infants... - Glycoconjugate vaccines to prevent group B streptococcal infectionsLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
Expert Opin Biol Ther 3:975-84. 2003..Results from these preclinical and clinical studies strongly suggest that GBS conjugate vaccines will be effective in preventing diseases caused by GBS... - Adherence to, invasion by, and cytokine production in response to serotype VIII group B StreptococciHiroshige Mikamo
Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 72:4716-22. 2004..These results suggest differences in immune responses to infection with GBS serotypes III and VIII... - Growth rate and oxygen regulate the interactions of group B Streptococcus with polarized respiratory epithelial cellsAtul K Johri
Channing Laboratory, Department of Medicine, Breigham and Women's Hospital, Harvard Med School, 181 Longwood Avenue, Boston, MA 02115, USA
Can J Microbiol 51:283-6. 2005..Growth rate and oxygen level strongly influence the interaction of GBS with polarized RECs and likely GBS pathogenicity... - Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3Lawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Infect Dis 186:1597-602. 2002..HIV-1 gp120-specific IgG with neutralizing activity against HIV-1 can be induced with conjugates containing gp120, env2-3, III, and TT... - Transcriptional and proteomic profiles of group B Streptococcus type V reveal potential adherence proteins associated with high-level invasionAtul K Johri
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 75:1473-83. 2007..Collectively, these data increase the number of potential GBS adherence factors and also suggest a role for these surface-associated proteins in initial pathogenic events... - Regulation and function of pilus island 1 in group B streptococcusShengmei Jiang
Division of Infectious Diseases, Children s Hospital Boston, Boston, Massachusetts, USA
J Bacteriol 194:2479-90. 2012..These findings shed new light on the complex nature of pilus regulation and function in modulating GBS interactions with the human host... - Oxygen regulates invasiveness and virulence of group B streptococcusAtul K Johri
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 71:6707-11. 2003..8 h, with oxygen) was more virulent in neonatal mice than was GBS grown under suboptimal invasion conditions (t(d) of 1.8 h, without oxygen), suggesting a positive association between in vitro invasiveness with DIVAS and virulence... - The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxisAnushua Sinha
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Vaccine 23:3187-95. 2005..Maternal GBS vaccination is predicted to prevent more cases of neonatal GBS disease than current practice and would prevent approximately one in 25 very preterm births... - Vaccines to prevent neonatal GBS infectionLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Semin Neonatol 7:315-23. 2002..Moreover, human antibodies elicited by the conjugate vaccines are functionally active both in vitro and in animal models of invasive GBS disease... - Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont Bacteroides fragilisMichael J Coyne
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:13099-104. 2008.... - Group B Streptococcus: global incidence and vaccine developmentAtul Kumar Johri
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
Nat Rev Microbiol 4:932-42. 2006..This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens... - Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adultsCarol J Baker
Section of Infectious Diseases, Department of Pediatrics, Room 302A, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States
Vaccine 25:55-63. 2007..V-TT vaccine-induced antibodies promoted opsonophagocytic killing of type V GBS and avidity maturation of V CPS-specific IgG... - Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and IIICarol J Baker
Sections of Infectious Diseases, Department of Pediatrics, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
J Infect Dis 188:66-73. 2003..These results support the feasibility of a multivalent vaccine for the 5 prevalent invasive disease-causing GBS CPS serotypes... - Identification of a universal Group B streptococcus vaccine by multiple genome screenDomenico Maione
Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
Science 309:148-50. 2005..Multigenome analysis and screening described here represent a powerful strategy for identifying potential vaccine candidates against highly variable pathogens... - Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccinesCarol J Baker
Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
J Infect Dis 189:1103-12. 2004..Infections caused by group B streptococcal (GBS) type V are increasingly common. Capsular polysaccharide (CPS)-protein conjugate GBS vaccines are immunogenic in healthy adults, but type V vaccines have not previously been tested...